Synaffix BV, of Amsterdam, said ADC Therapeutics Sarl, of Lausanne, Switzerland, has triggered a second target-specific license under their commercial license Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix's site-specific ADC technology.